Emulating VIEW 1 and VIEW 2 Clinical Trial Outcome Data Using the American Academy of Ophthalmology IRIS Registry
Access Your Copy of the Manuscript
This published study was conducted by Theodore Leng, MD, MS, and a team of researchers from Verana Health.
Groundbreaking research showing how curated real-world data (RWD) from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) was used to replicate primary outcome measures in a Phase III trial for a commonly used medication to treat blindness in the elderly population.
Explains how modeling was used to determine whether undetected biases had influenced the data.
Demonstrates the promise RWD has in reducing the time it takes to complete clinical trials, allowing pharmaceutical companies and device makers to get their products onto the market faster while ensuring their safety and efficacy.
Complete the form to access your copy.
Please do not send any Protected Health Information (PHI) when submitting this form. This form is not encrypted and it is not a suitable method for transmitting PHI. Any PHI sent to Verana Health via this form is deemed to be authorized by the subject of the PHI.